Shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) hit a new 52-week low during mid-day trading on Monday. The company traded as low as $11.12 and last traded at $11.18, with a volume of 56,449 shares. The stock had previously closed at $11.37.
Key Stories Impacting Janux Therapeutics
These are some of the JANX stories that stood out recently:
- Positive Sentiment: HC Wainwright raised its projected earnings per share (EPS) for Q4 2026 and each quarter of 2027, reflecting smaller expected losses. It also improved its full-year estimates for 2026 (to a loss of $1.48 per share from $1.69) and 2027 (to a loss of $1.92 from $2.36). Janux analyst estimate updates
- Neutral Sentiment: HC Wainwright reiterated its Buy rating, though its revised estimates still project losses in the coming years. Janux analyst estimate updates
- Negative Sentiment: The analyst cut its longer-term EPS forecasts: 2028 edged lower, while 2029 and 2030 were revised substantially down to losses of $3.06 and $2.04 per share, respectively. Those weaker outlooks could offset the improved near-term projections. Janux analyst estimate updates
Analysts Set New Price Targets
JANX has been the topic of several research analyst reports. Weiss Ratings restated a "sell (d-)" rating on shares of Janux Therapeutics in a research report on Friday, October 16th. Barclays upped their price objective on Janux Therapeutics from $14.00 to $15.00 and gave the stock an "underweight" rating in a research note on Friday, November 6th. HC Wainwright reiterated a "buy" rating on shares of Janux Therapeutics in a research report on Thursday. Truist Financial lifted their target price on Janux Therapeutics from $26.00 to $27.00 and gave the company a "buy" rating in a research note on Friday, November 6th. Finally, TD Cowen raised Janux Therapeutics to a "strong-buy" rating in a report on Monday, August 24th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have given a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat.com, Janux Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $36.92.
Check Out Our Latest Research Report on JANX
Janux Therapeutics Price Performance
The stock has a market cap of $658.94 million, a P/E ratio of -6.77 and a beta of 2.44. The stock's 50-day moving average is $16.80 and its two-hundred day moving average is $15.35.
Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.47) by $0.13. The company had revenue of $9.29 million during the quarter, compared to the consensus estimate of $8.03 million. On average, analysts anticipate that Janux Therapeutics, Inc. will post -1.59 EPS for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the company. GAMMA Investing LLC increased its holdings in shares of Janux Therapeutics by 67.4% in the third quarter. GAMMA Investing LLC now owns 1,642 shares of the company's stock worth $28,000 after purchasing an additional 661 shares during the last quarter. Versant Capital Management Inc boosted its stake in Janux Therapeutics by 42.8% during the second quarter. Versant Capital Management Inc now owns 2,615 shares of the company's stock valued at $40,000 after buying an additional 784 shares during the last quarter. Fulcrum Asset Management LLP boosted its stake in Janux Therapeutics by 3,391.2% during the third quarter. Fulcrum Asset Management LLP now owns 2,374 shares of the company's stock valued at $40,000 after buying an additional 2,306 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in Janux Therapeutics during the third quarter valued at approximately $54,000. Finally, Quantbot Technologies LP grew its holdings in Janux Therapeutics by 2,290.0% during the 2nd quarter. Quantbot Technologies LP now owns 5,497 shares of the company's stock valued at $84,000 after buying an additional 5,267 shares in the last quarter. Hedge funds and other institutional investors own 75.39% of the company's stock.
About Janux Therapeutics
(
Get Free Report)
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for cancer. The company's research focuses on engaging a patient's T cells to recognize and attack tumors. Janux's proprietary platforms are designed to keep certain immune therapies inactive until they reach the tumor environment, with the goal of limiting activity in healthy tissues. Its clinical-stage programs include candidates directed at targets such as PSMA and EGFR, and its broader pipeline includes additional investigational cancer therapies.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Janux Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Janux Therapeutics wasn't on the list.
While Janux Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.